Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.

Humans Crohn Disease / drug therapy Colitis, Ulcerative / drug therapy C-Reactive Protein / analysis Remission Induction Italy Gastrointestinal Agents / therapeutic use Treatment Outcome Retrospective Studies Inflammatory Bowel Diseases / drug therapy
Crohn’s disease remission safety ulcerative colitis vedolizumab

Journal

Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414

Informations de publication

Date de publication:
03 2023
Historique:
pubmed: 28 2 2023
medline: 15 3 2023
entrez: 27 2 2023
Statut: ppublish

Résumé

Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints. 729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6 We found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

Sections du résumé

BACKGROUND
Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.
RESEARCH DESIGN AND METHODS
Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.
RESULTS
729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6
CONCLUSION
We found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

Identifiants

DOI: 10.1080/14712598.2023.2185510 PMID: 36843568
pubmed: 36843568
doi: 10.1080/14712598.2023.2185510
doi:

Substances chimiques

vedolizumab 9RV78Q2002
C-Reactive Protein 9007-41-4
Gastrointestinal Agents 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

293-304

Auteurs

Giammarco Mocci (G)

Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.

Antonio Tursi (A)

Territorial Gastroenterology Service, ASL BAT, Andria, Italy.
Department of Medical and Surgical Sciences, Catholic University, School of Medicine, Rome, Italy.
ORCID: 0000-0001-5767-5541

Giovanni Maconi (G)

Division of Gastroenterology, "L. Sacco" University Hospital, Milan, Italy.

Giovanni Cataletti (G)

Division of Gastroenterology, "L. Sacco" University Hospital, Milan, Italy.

Beatrice Mantia (B)

Division of Gastroenterology, "L. Sacco" University Hospital, Milan, Italy.

Mariaelena Serio (M)

Division of Gastroenterology, "San Salvatore" Hospital, Pesaro, Italy.

Antonella Scarcelli (A)

Division of Gastroenterology, "San Salvatore" Hospital, Pesaro, Italy.

Cristiano Pagnini (C)

Division of Gastroenterology, "S. Giovanni - Addolorata" Hospital, Rome, Italy.

Maria Giovanna Graziani (MG)

Division of Gastroenterology, "S. Giovanni - Addolorata" Hospital, Rome, Italy.

Maria Carla Di Paolo (MC)

Division of Gastroenterology, "S. Giovanni - Addolorata" Hospital, Rome, Italy.

Giuseppe Pranzo (G)

Ambulatory for IBD Treatment, "Valle D'Itria" Hospital, Martina Franca (TA), Italy.

Ileana Luppino (I)

Division of Gastroenterology, "Annunziata" Hospital, Cosenza, Italy.

Pietro Paese (P)

Division of Gastroenterology, "Annunziata" Hospital, Cosenza, Italy.

Walter Elisei (W)

Division of Gastroenterology, A.O. "S. Camillo-Folanini", Rome, Italy.

Rita Monterubbianesi (R)

Division of Gastroenterology, A.O. "S. Camillo-Folanini", Rome, Italy.

Roberto Faggiani (R)

Division of Gastroenterology, A.O. "S. Camillo-Folanini", Rome, Italy.

Antonio Ferronato (A)

Digestive Endoscopy Unit, ULSS7 Pedemontana, Santorso (VI), Italy.

Barbara Perini (B)

Gastroenterology Unit, Azienda Ospedale-Università di Padova (AOUP), Padua, Italy.

Edoardo Savarino (E)

Gastroenterology Unit, Azienda Ospedale-Università di Padova (AOUP), Padua, Italy.
ORCID: 0000-0002-3187-2894

Francesca Maria Onidi (FM)

Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.

Laura Binaghi (L)

Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.

Paolo Usai Satta (P)

Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.

Elisa Schiavoni (E)

Division of Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Policlinico Universitario "A. Gemelli" IRCCS Foundation, Rome, Italy.

Daniele Napolitano (D)

Division of Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Policlinico Universitario "A. Gemelli" IRCCS Foundation, Rome, Italy.

Franco Scaldaferri (F)

Division of Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Policlinico Universitario "A. Gemelli" IRCCS Foundation, Rome, Italy.
School of Medicine, Catholic University, Rome, Italy.

Daniela Pugliese (D)

Division of Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Policlinico Universitario "A. Gemelli" IRCCS Foundation, Rome, Italy.
School of Medicine, Catholic University, Rome, Italy.

Roberta Pica (R)

Division of Gastroenterology, IBD Unit, "S. Pertini" Hospital, Rome, Italy.

Andrea Cocco (A)

Division of Gastroenterology, IBD Unit, "S. Pertini" Hospital, Rome, Italy.

Maddalena Zippi (M)

Division of Gastroenterology, IBD Unit, "S. Pertini" Hospital, Rome, Italy.

Stefano Rodino (S)

Division of Gastroenterology, "Ciaccio-Pugliese" Hospital, Catanzaro, Italy.

Ladislava Sebkova (L)

Division of Gastroenterology, "Ciaccio-Pugliese" Hospital, Catanzaro, Italy.

Giulia Rocco (G)

Division of Gastroenterology, "Belcolle" Hospital, Viterbo, Italy.

Carlotta Sacchi (C)

Division of Gastroenterology, "Belcolle" Hospital, Viterbo, Italy.

Costantino Zampaletta (C)

Division of Gastroenterology, "Belcolle" Hospital, Viterbo, Italy.

Federica Gaiani (F)

Gastroenterology and Endoscopy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Gianluigi De Angelis (G)

Gastroenterology and Endoscopy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Stefano Kayali (S)

Gastroenterology and Endoscopy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Libera Fanigliulo (L)

Division of Gastroenterology, "S.S. Annunziata" Hospital, Taranto, Italy.

Roberto Lorenzetti (R)

Division of Gastroenterology, "Nuovo Regina Margherita" Territorial Hospital, Roma, Italy.

Leonardo Allegretta (L)

Division of Gastroenterology, "Santa Caterina Novella" Hospital, Galatina (LE), Italy.

Stefano Scorza (S)

Division of Gastroenterology, "Santa Caterina Novella" Hospital, Galatina (LE), Italy.

Antonio Cuomo (A)

Division of Gastroenterology, "Umberto I" Hospital, Nocera Inferiore (SA), Italy.

Laura Donnarumma (L)

Division of Gastroenterology, "Umberto I" Hospital, Nocera Inferiore (SA), Italy.

Nicola Della Valle (N)

Division of Gastroenterology, A.O. "Ospedali Riuniti", Foggia, Italy.

Rodolfo Sacco (R)

Division of Gastroenterology, A.O. "Ospedali Riuniti", Foggia, Italy.
ORCID: 0000-0002-9887-7315

Giacomo Forti (G)

Division of Digestive Endoscopy, "S. Maria Goretti" Hospital, Latina, Italy.

Elisabetta Antonelli (E)

Gastroenterology & Hepatology Section, Department of Medicine & Surgery, University of Perugia, Perugia, Italy.

Gabrio Bassotti (G)

Gastroenterology & Hepatology Section, Department of Medicine & Surgery, University of Perugia, Perugia, Italy.
ORCID: 0000-0002-0237-1812

Chiara Iannelli (C)

Department of Health Science, University of Catanzaro, Catanzaro, Italy.

Francesco Luzza (F)

Department of Health Science, University of Catanzaro, Catanzaro, Italy.

Giovanni Aragona (G)

Division of Gastroenterology, "Guglielmo da Saliceto" Hospital, Piacenza, Italy.

Patrizia Perazzo (P)

Division of Gastroenterology, "Guglielmo da Saliceto" Hospital, Piacenza, Italy.

Angelo Lauria (A)

Division of Gastroenterology, A.O. "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.

Simona Piergallini (S)

Division of Gastroenterology, IBD Unit, "A. Murri" Hospital, Fermo, Italy.

Raffaele Colucci (R)

Digestive Endoscopy Unit, "San Matteo degli Infermi" Hospital, Spoleto (PG), Italy.

Maria Antonia Bianco (MA)

Division of Gastroenterology, "T. Maresca" Hospital, Torre del Greco (NA), Italy.

Costantino Meucci (C)

Division of Gastroenterology, "T. Maresca" Hospital, Torre del Greco (NA), Italy.

Gianmarco Giorgetti (G)

Digestive Endoscopy and Nutritional Unit, "S. Eugenio" Hospital, Rome, Italy.

Valeria Clemente (V)

Digestive Endoscopy and Nutritional Unit, "S. Eugenio" Hospital, Rome, Italy.

Serafina Fiorella (S)

Division of Gastroenterology, "Padre Pio" Hospital, Vasto (CH), Italy.

Antonio Penna (A)

Territorial Gastroenterology Service, ASL BA, Bari, Italy.

Antonio De Medici (A)

Territorial Gastroenterology Service, PST Catanzaro Lido, Catanzaro, Italy.

Marcello Picchio (M)

Division of General Surgery, "P. Colombo" Hospital, Velletri (Roma), Italy.

Alfredo Papa (A)

Division of Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Policlinico Universitario "A. Gemelli" IRCCS Foundation, Rome, Italy.
School of Medicine, Catholic University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Maladie de Crohn › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Rectocolite hémorragique › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du sang › Immunoprotéines › Protéine C-réactive › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Thérapeutique › Induction de rémission › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Régions géographiques › Europe › Italie › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents gastro-intestinaux › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Real-world efficacy and safety of vedolizumab...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Real-world efficacy and safety of vedolizumab...